Swiss pharma firm Sandoz will pay $478.5M to settle US generic drug price-fixing claims while denying wrongdoing.
Sandoz to pay $450 million following a settlement with 43 US states
Keystone-SDA
Sandoz has reached settlement agreements in the long-running US generic drug litigation involving 43 US states and territories, as well as a group of indirect resellers. The Basel-based pharmaceutical group will pay a total of just under $480 million as part of the settlement.
Generated with artificial intelligence.
This content was published on
Sandoz strikes US settlements to resolve generic drug price dispute
Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
Sandoz pagará US$ 450 milhões para encerrar litígios antitruste nos EUA
Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims
Curium buys Lantheus for $8B; Sandoz settles price-fixing cases
